{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:34:36Z","timestamp":1792226076952,"version":"4.4.0"},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We have identified two novel <jats:italic>ABL1<\/jats:italic> fusion genes in two patients with B\u2010cell acute lymphoblastic leukaemia (ALL) associated with a t(3;9)(p12;q34) and a t(5;9)(q23;q34), respectively. Molecular analysis revealed a <jats:italic>FOXP1\u2010ABL1<\/jats:italic> fusion for the t(3;9) and a <jats:italic>SNX2\u2010ABL1<\/jats:italic> fusion for the t(5;9). The fusions were confirmed by specific amplification of the genomic breakpoints using reverse transcription polymerase chain reaction. The identification of ALL with rare <jats:italic>ABL1<\/jats:italic> fusion partners is important because the leukaemia may respond to tyrosine kinase inhibitors in the same way as ALL patients with a classical <jats:italic>BCR\u2010ABL1<\/jats:italic> fusion gene.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08457.x","type":"journal-article","created":{"date-parts":[[2011,2,2]],"date-time":"2011-02-02T02:03:34Z","timestamp":1296612214000},"page":"43-46","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Identification of <i>FOXP1<\/i> and <i>SNX2<\/i> as novel <i>ABL1<\/i> fusion partners in acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"153","author":[{"given":"Thomas","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joannah","family":"Score","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hidalgo\u2010Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Ershler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FrancisH.","family":"Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70342-X"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3460176"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20060035"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2427"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.318"},{"key":"e_1_2_3_7_1","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) Treated with Imatinib","volume":"114","author":"Deininger M.","year":"2009","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.249"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20541"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.008094"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60457-2"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08457.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08457.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:52:24Z","timestamp":1697453544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08457.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08457.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08457.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"2011-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}